ANL (Adlai Nortye) Other Operating Expense: $0.08 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Adlai Nortye Other Operating Expense?

Adlai Nortye ANL -5.45% Other Operating Expense is $0.08 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Adlai Nortye's Other Operating Expense for the six months ended in Dec. 2025 was $0.22 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $0.08 Mil.

Adlai Nortye's quarterly Other Operating Expense declined from Dec. 2024 ($0.06 Mil) to Jun. 2025 ($-0.14 Mil) but then increased from Jun. 2025 ($-0.14 Mil) to Dec. 2025 ($0.22 Mil).

Adlai Nortye's annual Other Operating Expense declined from Dec. 2023 ($-0.42 Mil) to Dec. 2024 ($-1.43 Mil) but then increased from Dec. 2024 ($-1.43 Mil) to Dec. 2025 ($0.08 Mil).

Adlai Nortye Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Adlai Nortye's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adlai Nortye Other Operating Expense Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
-0.18 0.35 -0.42 -1.43 0.08

Adlai Nortye Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only -0.08 -1.49 0.06 -0.14 0.22

Adlai Nortye Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $0.08 Mil mean?
Adlai Nortye (ANL) has a Other Operating Expense of $0.08 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Adlai Nortye and its competitors.
Is Adlai Nortye's Other Operating Expense too high?
Adlai Nortye's current Other Operating Expense is $0.08 Mil.
How does Adlai Nortye's Other Operating Expense compare to OMER and PRME?
Adlai Nortye's Other Operating Expense of $0.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Adlai Nortye and its competitors. Adlai Nortye's current Other Operating Expense is $0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Other Operating Expense of $0.08 Mil. The current Other Operating Expense is $0.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Other Operating Expense is $0.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adlai Nortye Business Description

Other Exchanges N2U0:Germany
Address 685 US Highway 1, New Jersey Biotechnology Development Center, 2nd Floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.